An Open Label, Phase 2 Study of Ibrutinib in Combination With Rituximab and Lenalidomide in Previously Untreated Subjects With Follicular Lymphoma
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 03 Apr 2018
At a glance
- Drugs Ibrutinib (Primary) ; Lenalidomide; Rituximab
- Indications Follicular lymphoma
- Focus Therapeutic Use
- 27 Mar 2018 Planned number of patients changed from 60 to 56.
- 27 Mar 2018 Status changed from recruiting to active, no longer recruiting.
- 09 Feb 2018 Planned End Date changed from 1 Apr 2019 to 1 Apr 2021.